What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diffuse Large B-cell Lymphoma
- Main trialPhase 3
- “This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.”In the company’s words, NCT06929624 on ClinicalTrials.gov
Other drugs for Diffuse Large B-cell Lymphoma
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- AcalabrutinibAstraZeneca · Phase 3
- EpcoritamabGenmab · Phase 3
- TisagenlecleucelNovartis · Phase 3
- Zilovertamab vedotinMerck & Co. · Phase 3
Coming up1
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Mar 2027 | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma | |
| Phase 1/2Unknown | Dec 2025 | A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma | |
| Phase 1Unknown | 31 Mar 2024 | A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026